by sherry | Dec 20, 2021 | Press Release
“The joint study has confirmed that personalized PBM dosing is key to MDD treatment.” Irvine, Calif.—Niraxx Light Therapeutics, a leader in wearable neurotechnology, today announced recent study findings supporting the company’s personalized PBM...
by sherry | Feb 8, 2021 | Press Release
“We think the device’s wearability—ability to deliver treatment whenever and wherever—will change the care paradigm for depression.” Irvine, Calif. — Niraxx Light Therapeutics, a leader in wearable neurotechnology, today announced the initiation of a...
by sherry | Mar 21, 2020 | Blog
It starts as a sadness, then I feel myself shutting down, becoming less capable of coping. Eventually I just feel numb and empty. — Mind (UK mental health advocacy group) This visceral description of depression captures only one of the many faces of the illness,...
by sherry | Mar 20, 2020 | Peer-Reviewed Publications
Major depressive disorder (MDD) is the third leading cause of global disability [1], yet not everyone diagnosed with the condition seek treatment. Roughly 43% of primary care patients who experience a 6-month anxiety or depressive disorder diagnosis do not receive...
by sherry | Mar 19, 2020 | Peer-Reviewed Publications
Current treatment of depression has significant limitations. Antidepressant medication is the first-line treatment for depression, but it is not suitable for everyone. Askalsky and losifescu cited “more than one-third of [Major Depressive Disorder] patients do...
